Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Receivables (2017 - 2025)

Aclaris Therapeutics has reported Receivables over the past 9 years, most recently at $194000.0 for Q2 2025.

  • Quarterly results put Receivables at $194000.0 for Q2 2025, down 72.29% from a year ago — trailing twelve months through Jun 2025 was $194000.0 (down 72.29% YoY), and the annual figure for FY2024 was $318000.0, up 6.71%.
  • Receivables for Q2 2025 was $194000.0 at Aclaris Therapeutics, down from $250000.0 in the prior quarter.
  • Over the last five years, Receivables for ACRS hit a ceiling of $939000.0 in Q2 2021 and a floor of $194000.0 in Q2 2025.
  • Median Receivables over the past 5 years was $540500.0 (2022), compared with a mean of $529111.1.
  • Biggest five-year swings in Receivables: skyrocketed 62.41% in 2024 and later crashed 72.29% in 2025.
  • Aclaris Therapeutics' Receivables stood at $647000.0 in 2021, then fell by 25.19% to $484000.0 in 2022, then tumbled by 38.43% to $298000.0 in 2023, then rose by 6.71% to $318000.0 in 2024, then tumbled by 38.99% to $194000.0 in 2025.
  • The last three reported values for Receivables were $194000.0 (Q2 2025), $250000.0 (Q1 2025), and $318000.0 (Q4 2024) per Business Quant data.